Sciele announces Ostiva for women at risk for osteoporosis

By Lisa Kerner

Charlotte, N.C., Sept. 28 - Sciele Pharma, Inc. believes its newest product, Ostiva, an oral prescription nutritional supplement for women, will open new doors for the company, according to president and chief executive officer Patrick Fourteau.

Fourteau commented on the new product at the UBS Global Life Sciences Conference Thursday in New York.

He spent some time discussing Sciele's 2003 "turnaround year," noting that since then, revenue growth has reached close to 50%, compounded. Earnings per share over the past three years have grown 43%, while first-half 2006 results show a 54% revenue growth.

The new Ostiva product for bone health, however, was the main announcement. The product, formulated with Metafolin, calcium and vitamin D, is aimed at women who are unable to completely metabolize folic acid. Women in a broad age range can benefit from the supplement, including menopausal and post-menopausal women, the company said.

Ostiva complements and expands Sciele's women's health product portfolio, Fourteau added.

Sciele is an Atlanta pharmaceutical company specializing in products for cardiovascular/metabolic and women's health.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.